Blog
Cancer innovation needs better data—not just better drugs
ISPOR 2025: Trends in the prescribing and dispensing of GLP-1 anti-obesity medications among adults with cardiovascular disease
ISPOR 2025: Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation
ISPOR 2025: Characteristics and adherence of patients initiating injectable cabotegravir for HIV treatment or prevention
Truveta leads a new era in cancer research with the most complete, representative, and timely real-world data on all cancers
Top 5 takeaways from Truveta Symposium 2025
Women’s health: Pain medication remains rare for women receiving IUDs
